Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
Designation is driven by compelling Phase 2 clinical data in patients with complicated Staphylococcus aureus bacteremia showing AP-SA02…
Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlite™ in Landmark CREDENCE Trial
New analysis supports DNlite™ for earlier renal risk stratification in patients with type 2 diabetes and chronic kidney…
First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control
Phase 2 Study Results Highlight Use of Once-Daily Injection for Weight Loss and Reduction in Insulin Use NEW…
Avant Technologies and Austrianova Advancing α-Klotho Cell Therapy as Mayo Clinic Study Links Low α-Klotho Levels to Poor Cardiovascular Survival
LAS VEGAS, Dec. 9, 2025 /PRNewswire/ — Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an emerging biotechnology…
Vincere Cancer Center Begins Recruitment for Clinical Studies of Pioneering Breast Cancer Screen for Women at High Risk
US cancer center partners with Syantra Inc. for further testing of Onco-ID Breast, a whole blood mRNA test…
FDA Issues Formal Guideline Waiving Clinical Efficacy Studies for Biosimilars, Confirming Professor Niazi’s 15-Year Campaign to Cut Biologic Drug Costs
A Landmark Regulatory Shift Validates Professor Sarfaraz K. Niazi’s Vision to Make Biologics as Affordable as Generics CHICAGO,…